Citeline, Biomedtracker: see the drug development process th...
Catch up on any missed COVID-19 24 hour webinar sessions
Using real-time development, pipeline event and impact tracking, and in-depth disease and market landscape reports, this webinar looks at the market dynamics, opportunities, threats, and payer pressures for marketed HIV drugs, and examines the likelihood of approval for late-phase pipeline drugs.
Mr. Haydock & Mr. Haas used the exclusive information within Datamonitor Healthcare and Biomedtracker to present a view of the market for HIV drugs. Informa Pharma Intelligence forecasts HIV sales revenues to increase in the US and five major EU markets to a peak of $22.7bn in 2024 before generic erosion triggers a market decline.
In this recording you will learn about the significant market shifts. It covers:
Datamonitor Healthcare: data analysis and insight, Pink Shee...
By Tara Hansen
The FDA Oncology Center of Excellence’s ‘industry-wide evaluation’ of accelerated approvals has already led to withdrawals of four PD-1/PD-L1 inhibitor indications, with the Oncologic Drugs Advisory Committee set to review another six in late April. Over the next two years, an additional five indications may be up for review.
Datamonitor Healthcare: data analysis and insight
Biopharma’s accomplishments in tackling the global COVID-19 pandemic, unlike advances within oncology such as cell therapies and checkpoint inhibitors, or functional cures for HIV and hepatitis C, have captured the public’s imagination.
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Our team is always happy to hear from you. Please call us at:
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: